Liquidia Corporation

Good morning and welcome everyone to the Liquidia Corporation's full year 2022 financial results and corporate update conference call. My name is Chris and I'll be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded And I will now hand the call over to Jason Adair, Senior Vice President, Corporate Development and Strategy. Sir, please go ahead.

Thank you, Chris. It's my pleasure to welcome everyone to Liquidity's full year 2022 financial results and corporate update conference call. Joining the call today are Chief Executive Officer, Roger Jeff, Chief Medical Officer, Dr. Rajiv Sagar, Chief Financial Officer, Michael Cassetta, and General Counsel, Rusty Schundler. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. The company will file its 10-K on Monday, March 20th. I would now like to turn the call over to Roger for our prepared remarks, after which he will open the call up for your questions.

Thank you, Jason. Good morning, everyone, and thank you for joining us. As I look back on 2022, my first year as CEO at Liquidia, I remain humbled to have joined an organization Organizations have poised to join the company in an operational role which is related to the potential of Utrepia to universally transform the problem of cyclone therapy from a high-burden treatment option to a low-burden option for patients. Specifically, four key attributes resonated loudly with me. Utrepia's tolerability, Utrepia's titratability, Utrepia's durability, and Utrepia's usability and portability. These four attributes continue to resonate with me and support my belief that eutrefia has the potential to be the prostacyclin therapy of first choice and best-in-class inhaled therapy for patients with either pH or pH ILD. The open-label extension data that continues to mature only further complements my belief in the commercial potential of eutrefia to participate significantly in what is now the fastest-growing segment of pH and pH ILD in the prostanil market. The other main excitement for joining us was the event strength of the entire organization and our internal capability to manufacture drug substance in-house. Of course, it also didn't hurt that we already had tentative approval and labeling in hand. In 2022, we made key strategic hires to strengthen our core capabilities, and in concert with our legal success in 2022, Liquidia is now well-positioned to maximize the commercial uptake of eutropia I'd like to now turn the call over to Rajiv Sagar, our CMO, and one of those key 2022 hires to expand on why we are so excited about Dutrevi's unique product profile and why we believe we are ideally positioned to provide a differentiated, best-in-class option for patients. Rajiv?